Dr. Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. In her current position as a Sr Research Fellow at Eli Lilly & Company, she is responsible for the design and execution of nonclinical safety assessments and for all nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases.
Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research (CIIT, RTI), risk assessment in the chemical & agrochemical industry (FMC Corp), and safety assessment of pharmaceuticals (Sphinx, Eli Lilly). Dr. Buckley frequently lectures in various educational and professional settings and has authored numerous journal articles and book chapters concerning approaches to pharmaceutical safety assessment and the toxicologic assessment of environmental contaminants.
Dr. Buckley has served as a Board member of the American Board of Toxicology (ABT, 2004-2007) and the Academy of Toxicological Sciences (ATS, 2015-2018) and on the Councils of the Society of Toxicology (SOT, 2012-2016) and the American College of Toxicology (ACT, 2021 Past President). Within the Innovation and Quality (IQ) Consortium for Pharmaceutical Development, she has actively contributed to various inter-industry initiatives as a member of the DruSafe Leadership Group.